N-n Or N=c(-n)-n Containing (e.g., Hydrazines, Hydrazones, Or Guanidines, Etc.) Patents (Class 514/565)
-
Publication number: 20110313011Abstract: A method for increasing the bioabsorption of amino acids in a human or animal is disclosed. The method includes administering to the human or animal a pharmaceutically effective amount of an amino acid compound consisting essentially of a nitrate or nitrite of an amino acid selected from the group consisting of Arginine, Agmatine, Beta Alanine, Citrulline, Creatine, Glutamine, L-Histidine, Isoleucine, Leucine, Norvaline, Ornithine, and Valine.Type: ApplicationFiled: November 15, 2010Publication date: December 22, 2011Applicant: THERMOLIFE INTERNATIONAL, LLCInventors: Ronald Kramer, Alexander Nikolaidis
-
Publication number: 20110313042Abstract: An amino acid composition is disclosed. The composition includes: at least one constituent selected from the group consisting of a nitrate, a nitrite, and both; and at least one constituent amino acid selected from the group consisting of Arginine, Agmatine, Beta Alanine, Citrulline, Creatine, Glutamine, L-Histidine, Isoleucine, Leucine, Norvaline, Ornithine, Valine, Aspartic Acid, Cysteine, Glycine, Lysine, Methionine, Proline, Tyrosine, and Phenylalanine Also disclosed are a method for increasing the bioabsorption of Amino Acids in a human or animal and a method for increasing vasodilative characteristics of Amino Acids in a human or animal.Type: ApplicationFiled: March 2, 2011Publication date: December 22, 2011Applicant: THERMOLIFE INTERNATIONAL, LLCInventors: Ronald Kramer, Alexander Nikolaidis
-
Publication number: 20110312882Abstract: Provided are compositions comprising beta-alanylhistidine peptides and/or beta-alanines, and methods for administering these peptides and amino acids. In one aspect, the compositions and methods cause an increase in the blood plasma concentrations of beta-alanine and/or creatine.Type: ApplicationFiled: August 22, 2011Publication date: December 22, 2011Applicant: Natural Alternatives International, Inc.Inventors: Roger Harris, Mark Dunnett
-
Publication number: 20110313043Abstract: Methods for increasing athletic performance, distribution of various Amino Acids to muscles, and solubility of various Amino Acids in a human or animal by administering an amino acid composition that includes: at least one constituent selected from the group consisting of a nitrate, a nitrite, and both; and at least one constituent amino acid selected from the group consisting of Arginine, Agmatine, Beta Alanine, Citrulline, Creatine, Glutamine, L-Histidine, Isoleucine, Leucine, Norvaline, Ornithine, Valine, Aspartic Acid, Cysteine, Glycine, Lysine, Methionine, Proline, Tyrosine, and PhenylalanineType: ApplicationFiled: March 2, 2011Publication date: December 22, 2011Applicant: THERMOLIFE INTERNATIONAL, LLCInventors: Ronald Kramer, Alexander Nikolaidis
-
Publication number: 20110300232Abstract: Nitric Oxide (NO) acts as double-edged sword, which induces and prevents cell death, depending on various factors. The mechanism for the NO regulation of cells is not fully understood. The present invention provides experiment design methods and therapy design methods leveraging viable hypothesis supported by current research findings. This invention determines the effects of NO by controlling the majority parameters such as the steady-state concentration of NO, duration of NO exposure and the local level of oxygen. The experiment designs are structured to improve understanding of NO regulation of cells, and further can be directly adapted for therapy design. The invention directs these experiment design and therapy design methods to the study and treatment of cancer. In an application, the effects of exogenous NO on inducible Nitric Oxide Synthase (iNOS) expression and signal transduction in ovarian cancer is applied to drug discovery and therapy design for ovarian and other cancers.Type: ApplicationFiled: June 7, 2011Publication date: December 8, 2011Inventor: Pooncharas Tipgunlakant
-
Patent number: 8067381Abstract: Provided are compositions comprising beta-alanylhistidine peptides and/or beta-alanines, and methods for administering these peptides and amino acids. In one aspect, the compositions and methods cause an increase in the blood plasma concentrations of beta-alanine and/or creatine.Type: GrantFiled: August 22, 2011Date of Patent: November 29, 2011Assignee: Natural Alternatives International, Inc.Inventors: Roger Harris, Mark Dunnett
-
Patent number: 8063104Abstract: Compounds of formula (I) have been found to be useful as inhibitors of DDAH.Type: GrantFiled: November 11, 2005Date of Patent: November 22, 2011Assignee: UCL Business PLCInventors: Patrick John Thompson Vallance, James Mitchell Leiper, David Lawrence Selwood, Sharon Rossiter, Basil Hartzoulakis
-
Publication number: 20110275649Abstract: Novel combinations comprising HMG CoA reductase inhibitors, or statins, with partial fatty acid oxidation inhibitors (pFOXi), and methods for their use, are disclosed. These combinations are useful in preventing or reducing the risk of developing diabetes which results from therapy with a statin.Type: ApplicationFiled: May 3, 2011Publication date: November 10, 2011Applicant: Palmetto Pharmaceuticals LLCInventor: Wayne H. Kaesemeyer
-
Publication number: 20110269833Abstract: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.Type: ApplicationFiled: December 7, 2010Publication date: November 3, 2011Inventors: Oron Yacoby-Zeevi, Mara Nemas
-
Publication number: 20110263540Abstract: Small-molecule inhibitors of a protein synthesis inhibiting toxin, e.g., ricin, abrin, Shiga, and Shiga-like toxins, as well as methods of using the inhibitors are provided. Further provided are methods of identifying small-molecule inhibitors of a protein synthesis inhibiting toxin.Type: ApplicationFiled: July 24, 2009Publication date: October 27, 2011Inventors: Yuan-Ping Pang, Nilgun Ereken Tumer, Charles B. Millard
-
Publication number: 20110257075Abstract: The present invention relates to the use of guanidinoacetic acid and/or salts thereof as feed additive, in predominantly vegetarian diets, in particular use being made of salts with hydrochloric acid, hydrobromic acid and phosphoric acid. The use proceeds especially in individual doses from 0.01 to 100 g/kg of feed in the form of powders, granules, pastilles or capsules, the feed additive also being able to be used in combination with other physiologically active materials of value. The claimed use which is suitable especially for breeding and growing livestock, has recourse to a compound which is in particular stable in aqueous solution, can be converted to creatine under physiological conditions, and, in contrast to other guanidine derivatives, is completely available to physiological sectors of use.Type: ApplicationFiled: June 21, 2011Publication date: October 20, 2011Inventors: THOMAS GASTNER, Hans-Peter Krimmer
-
Publication number: 20110257202Abstract: Disclosed herein are compositions and methods for treating chronic kidney disease and/or a metabolic imbalance. Specifically exemplified herein are methods involving the coadministration of a RAS inhibitor with a conjunctive agent that improves endothelial NO or endothelial function. Also disclosed are methods of treating a patient exhibiting symptoms of a stage of chronic kidney disease and at least one symptom of a metabolic imbalance, such as one or more diagnostic criteria of the metabolic syndrome.Type: ApplicationFiled: October 19, 2009Publication date: October 20, 2011Inventors: Richard J Johnson, Takahiko Nakagawa
-
Publication number: 20110257236Abstract: [Problem] A valine, isoleucine, leucine mixture which is excellent in the reduction of bitter taste and improved dissolution speed is provided. [Solving Means] The above problem is solved by a solid solution composed of three amino acids of valine, isoleucine, leucine, and a solid solution composed of these and at least one of acid selected from the group consisting of neutral aliphatic amino acid, neutral hydroxy amino acid, neutral acid amide amino acid, acidic amino acid, basic amino acid, hydroxy acid.Type: ApplicationFiled: April 27, 2011Publication date: October 20, 2011Applicant: AJINOMOTO CO., INC.Inventors: Masako KOYAMA, Momoko Kimura, Tetsuo Tanegawa
-
Publication number: 20110245345Abstract: The present invention relates to a topical composition to enhance sexual response. The composition includes L-arginine, trans-resveratrol, and a topical carrier wherein L-arginine is present in an amount not greater than about 10% and trans-resveratrol is present in an amount not greater than about 10% based upon the weight of the total composition. The invention also relates to a method of enhancing sexual response by topically applying the topical composition to the genetalia of a human, and an integrated product including the topical composition, a container for instantaneous delivery, and instructions for use.Type: ApplicationFiled: June 13, 2011Publication date: October 6, 2011Inventors: Teri Amato, Chandrakala Agarwala
-
Publication number: 20110245344Abstract: An object of the invention is to provide a novel arginine derivative and a cosmetic satisfactory in compatibility with the skin and hair, excellent in skin softening effect and skin-conditioning effect, and satisfactory in use feeling with little sticky feeling and tense feeling. Such present invention relates to an arginine derivative represented by the following general formula (1): wherein R1 and R2 are a hydrogen atom or a linear or branched monohydroxyalkyl group having 2 to 3 carbon atoms and at least one of R1 and R2 represents a linear or branched monohydroxyalkyl group having 2 to 3 carbon atoms; and R3 represents a hydrogen atom, an alkali metal atom, an ammonium, or an organic ammonium, and a cosmetic containing the same mixed therein.Type: ApplicationFiled: December 25, 2009Publication date: October 6, 2011Applicant: NOF CORPORATIONInventors: Kazuaki Wakita, Susumu Tanaka, Kei-ichi Maruyama
-
Publication number: 20110236508Abstract: A formulation comprising large quantities of l-arginine and/or fat plaque dissolving agents which is palatable, stench free, and does not evoke nausea. The formulation is adapted to facilitate the adsorption of l-arginine to the blood system and to introduce high levels of l-arginine and/or other fat plaque dissolving agents such as EDTA, its derivatives or its salts into the blood system which are sufficient for effectively dissolving fat plaques in the artery. The formulation comprises at least 10% (w/w) L-arginine, edible organic acids, emulsifier(s), preservatives, flavorings, ethanol and water.Type: ApplicationFiled: November 30, 2009Publication date: September 29, 2011Inventors: Benzion Geshuri, Orna Levin
-
Publication number: 20110236502Abstract: The vitamin strip is made with gel, film, or dissolvable material safe for human consumption. It can encompass all the vitamins, minerals, medicines, or meal replacement elements safe for human intake. The vitamin strip (V1) can be made as a whole or as a strip of edible dissolvable material with any vitamin(s), mineral(s), medicine(s), or meal replacement element(s) safe for human consumption on the strip of edible dissolvable material.Type: ApplicationFiled: March 29, 2010Publication date: September 29, 2011Inventor: Joseph Marcel Guillory
-
Patent number: 8026385Abstract: Creatine oral supplementation using creatine hydrochloride salt, that may be added to a liquid or other beverage, or may be also used as an additive to solid oral dosages, or as a supplement, and which may be consumed by the athlete, or other party looking for immediate supplementation of strength, and may be added as a supplement within feed to livestock, in the veterinary area.Type: GrantFiled: June 3, 2009Date of Patent: September 27, 2011Assignee: Vireo Systems, Inc.Inventors: Donald W. Miller, Jonathan L. Vennerstrom, Mark C. Faulkner
-
Publication number: 20110218158Abstract: Cytosine deaminase inhibitors and methods for identifying inhibitors of the anti-retroviral activity of APOBEC3G are described.Type: ApplicationFiled: September 22, 2009Publication date: September 8, 2011Inventors: Reuben S. Harris, Ming Li
-
Publication number: 20110217364Abstract: A modification of pharmacokinetics of suramin by use of amino compounds in modification of lipophilicity and protein binding characteristics for tackling the physico-chemical properties of suramin that gives it poor distribution in the body; formulating the resulting product in a form that leads to targeting body fluids like the lymphatic system when administered in a specific way; and determining the route of administration that maximizes targeting with a view to reducing the dosage so as to limit toxicity, hence increase tolerance by patient.Type: ApplicationFiled: July 10, 2009Publication date: September 8, 2011Inventor: Sammy O. Opiyo
-
Publication number: 20110213034Abstract: Disclosed are amphetamine prodrug compositions comprising at least one non-standard amino acid conjugate of amphetamine, a salt thereof, or a combination thereof, and methods of using the same.Type: ApplicationFiled: February 17, 2011Publication date: September 1, 2011Inventor: Travis C. Mickle
-
Publication number: 20110213033Abstract: The present invention relates to a skin conditioner comprising the compound represented with the general formula: (wherein, the symbols are the same as those defined in the text). Examples of active ingredients of the present invention include L-arginine and ethanolamine. These active ingredients can be acquired as chemical synthesis products, or they may also be acquired in the form of natural substances. Preferable examples of natural substances include substances containing L-arginine and/or ethanolamine obtained from rice. The skin conditioner as claimed in the present invention demonstrates remarkable effectiveness as an agent for the prevention and treatment of atopic dermatitis and as a skin moisture retention agent.Type: ApplicationFiled: January 25, 2011Publication date: September 1, 2011Applicant: Kabushiki Kaisha SokenInventors: Takashi TOKUYAMA, Megumi JO
-
Publication number: 20110206781Abstract: Described herein are methods, compositions and kits related to manipulating hematopoietic stem cells (HSC) and more particularly to methods, compositions and kits related to increasing the number of hematopoietic stem cells in vitro, ex vivo and/or in vivo. Also described are methods, compositions and kits related to making an expanded population of HSC and methods, compositions and kits related to using the expanded population of HSC. For example, HSC growth may be enhanced by contacting the nascent stem cells or HSC with an agent that stimulates the nitric oxide signaling pathway.Type: ApplicationFiled: May 28, 2009Publication date: August 25, 2011Inventors: Leonard I. Zon, Trista E. North, Wolfram Goessling
-
Patent number: 8003141Abstract: Materials derived from cinnamon can be administered orally to humans or animals for the purpose of controlling blood glucose as well improving glucose tolerance. Controlling glucose metabolism is essential for those with impaired glucose metabolism as is the case for those with Type II diabetes where insulin function is not properly functioning. Such administration can also be used for the purpose of enhancing nutrient transport for purposes of athletic performance and controlling bodyweight and body fat levels. Similarly related, such administration can also be used for the purpose of enhancing creatine transport into excitable tissues such as skeletal muscle. The material can be administered as extracts of cinnamon and can be administered in a variety of ways including capsules, tablets, powdered beverages, bars, gels or drinks.Type: GrantFiled: March 16, 2009Date of Patent: August 23, 2011Assignee: Integrity NutraceuticalsInventors: Peter Miller, Timothy Romero
-
Publication number: 20110195115Abstract: The present invention provides a hydrophilic amino acid-containing preparation wherein the taste of the hydrophilic amino acid is improved without damaging the appearance, flavor, storage stability and so on. It is further intended to provide a hydrophilic amino acid-containing preparation in which quick release of the hydrophilic amino acid from the preparation is assured, if necessary. It is furthermore intended to provide a hydrophilic amino acid-containing preparation where a solid agent containing a hydrophilic amino acid is coated with a coating agent comprising a flavoring agent and a water-soluble high molecular material.Type: ApplicationFiled: February 10, 2011Publication date: August 11, 2011Applicant: AJINOMOTO CO., INC.Inventors: Masayuki TANAKA, Manabu Kitazawa, Chisato Makino, Kazuhiro Takanosu
-
Publication number: 20110189110Abstract: The present invention is directed to methods and compositions comprising a basic amino acid, e.g., arginine, for the treatment of dry mouth.Type: ApplicationFiled: February 6, 2009Publication date: August 4, 2011Applicant: Colgate-Palmolive CompanyInventors: Rajnish Kohli, Richard Scott Robinson, Richard J. Sullivan, Diane Cummins, Jay Jayaraman, MarryAnn Filadelfi-Keszi
-
Publication number: 20110171193Abstract: Provided herein are methods and materials for treating pulmonary hypertension (PH) in a subject. Also provided herein is a method of diagnosing whether a has PH by detecting a PH marker. A PKG pulmonary hypertension marker has been identified and may be useful in predicting PH disease progression and assessing a subject's response to PH therapy.Type: ApplicationFiled: June 12, 2009Publication date: July 14, 2011Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventors: You-Yang Zhao, Asrar B. Malik
-
Publication number: 20110166232Abstract: A method of treating nocturia in a human individual includes administering dosages of creatine to the individual; and reducing the dosages of creatine to the individual responsive to an increase in difficulty of the individual to initiate urination. Another example method includes reducing the dosages of creatine to the individual responsive to an increase in nocturnal urination frequency of the individual. A dosing system includes doses of creatine for treating nocturia in a human individual and is configured for reduced doses for administration in response to an increase in one or more nocturia symptoms. Various other methods as well as compositions, systems, etc., are also disclosed.Type: ApplicationFiled: December 23, 2010Publication date: July 7, 2011Inventor: Robert A. Hander
-
Publication number: 20110130460Abstract: The present invention generally relates to increasing the efficiency of usage of an ingested biologically active substance by a body. In particular, the present invention relates to ways to improve the efficiency of utilization of ingested creatine in a body, in particular to increase the storage of creatine in the body. One embodiment of the present invention is the use of a combination comprising creatine and a viscous soluble fiber for the preparation of a composition to increase the storage of creatine in the body.Type: ApplicationFiled: August 14, 2008Publication date: June 2, 2011Applicant: NESTEC S.A.Inventors: John Bruce German, Jacques Edouard Decombaz, Pierre Wuersch, Evelyne Greet Vandeputte
-
Publication number: 20110117219Abstract: The invention relates to ether guanidines of the general formulae (I) and/or salts or hydrates thereof, in which R1=—CH2—CH2—CH2—O—R3 where R3 is, independently of the others, hydrocarbon radicals having greater than or equal to 10 carbon atoms, where part of the ether guanidines has radicals R3 which are branched and part of the ether guanidines has radicals R3 which are unbranched, and R2=independently of the others H or an optionally branched, optionally double-bond-containing hydrocarbon radical having 1 to 30 carbon atoms, and use thereof in hair treatment compositions and hair aftertreatment compositions, in particular for preventing damage by chemical treatment compositions and for repairing hair which is already damaged.Type: ApplicationFiled: May 28, 2009Publication date: May 19, 2011Applicant: EVONIK GOLDSCHMIDT GMBHInventors: Oliver Springer, Peter Muss, Burghard Gruening, Ursula Maczkiewitz, Mike Farwick, Peter Lersch
-
Publication number: 20110112188Abstract: The invention relates to methods of inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin thereby treating or prevention various diseases, disorders or conditions. Additionally, the invention relates to treatment of various diseases, disorders or conditions associated with or mediated by oxidative stress since 3DG induces ROS and AGEs, which are associated with the inflammatory response caused by oxidative stress.Type: ApplicationFiled: September 9, 2010Publication date: May 12, 2011Inventors: ANNETTE TOBIA, FRANCIS KAPPLER
-
Patent number: 7932291Abstract: The use of L-carnitine and its alkanoyl derivatives, optionally in the form of a pharmaceutically acceptable salt, as osmotic agents in the preparation of solutions for medical use, particularly for peritoneal dialysis, is described.Type: GrantFiled: October 12, 2004Date of Patent: April 26, 2011Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventor: Arduino Arduini
-
Publication number: 20110085993Abstract: The present invention relates to the use of creatine compounds such as, for example, creatine, creatine phosphate or analogs of creatine, such as creatine-pyruvate, creatine-ascorbate, cyclocreatine, 3 guanidinopropionic acid, guanidinoacetate, homocyclocreatine, guanidino benzoates as energy generating systems and antioxidants for preservation of skin against adverse aging effects and damage secondary to insults such as harmful sun radiations, stress and fatigue. The creatine compounds which can be used in the present method include (1) creatine, creatine phosphate and analogs of these compounds which can act as substrates or substrate analogs for creatine kinase; (2) molecules that mimic the biological activity of creatine (3) molecules that modulate the creatine kinase system.Type: ApplicationFiled: May 11, 2010Publication date: April 14, 2011Applicant: AVICENA GROUP, INC.Inventor: Rima KADDURAH-DAOUK
-
Publication number: 20110077198Abstract: The present invention relates to compositions and methods for preventing and treating a condition in a mammalian subject that include at least one inhibitor of double stranded RNA dependent protein kinase (PKR-I) prior to or concurrently with the treatment, wherein the treatment results to an inhibition of activation of dsRNA-dependent protein kinase. The compositions and methods of the present invention further include at least one potentiator that further enhances the inhibition of phosphorylation by PKR-I.Type: ApplicationFiled: October 3, 2008Publication date: March 31, 2011Inventors: Michael John Tisdale, Helen Laura Eley, Steve Thomas Russell, Kevin Burke Miller
-
Patent number: 7914814Abstract: A preparation is disclosed for producing enhanced blood flow in tissue thus causing beneficial effects such as promoting hair growth on scalp tissue lacking sufficient hair, restoring normal sexual function in males with erectile dysfunction. Specifically, this is a preparation which provides local delivery of the amino acid L-arginine, an important biological precursor to the main substance which is responsible for relaxation of blood vessels permitting enhancement of blood flow. In the preferred embodiments, the L-arginine is provided so that it can be topically applied to the scalp or penis. The preparation also contains an agent which aids in the transfer of L-arginine into the tissue. In the preferred embodiments this agent overcomes the resistance to transfer caused by the high charge density of L-arginine. In the preferred embodiments this means is high ionic strength created by addition of choline chloride, magnesium chloride and sodium chloride.Type: GrantFiled: September 17, 1997Date of Patent: March 29, 2011Assignee: Strategic Science & Technologies, LLCInventor: Eric T. Fossel
-
Publication number: 20110071168Abstract: There is provided a method of promoting neurogenesis by administering a therapeutic amount of a nitric oxide donor compound to a patient in need of neurogenesis promotion. Also provided is a compound for providing neurogenesis having an effective amount of a nitric oxide donor sufficient to promote neurogenesis. A nitric oxide compound for promoting neurogenesis is also provided. Further, a method of augmenting the production of brain cells and facilitating cellular structural and receptor changes by administering an effective amount of a nitric oxide donor compound to a site in need of augmentation is provided. There is provided a method of increasing both neurological and cognitive function by administering an effective amount of a nitric oxide donor compound to a patient.Type: ApplicationFiled: February 1, 2010Publication date: March 24, 2011Inventors: Michael Chopp, Rui L. Zhang
-
Publication number: 20110060046Abstract: Provided is an agent for the prophylaxis or improvement of functional gastrointestinal disorders, which contains glutamic acid or a salt thereof other than arginine glutamate, and arginine or a salt thereof other than arginine glutamate, as active ingredients. The prophylactic or improvement agent can be produced conveniently and at low cost and is high safe and particularly effective for functional dyspepsia (FD) such as abdominal pain, heavy stomach, heartburn and the like, and upper gastrointestinal dysfunction such as esophageal reflux (GERD) and the like.Type: ApplicationFiled: September 10, 2010Publication date: March 10, 2011Applicant: AJINOMOTO CO. INC.Inventors: Shinichi Fujita, Ikumi Ishibashi, Saori Ogawa, Manabu Suzuki
-
Publication number: 20110059906Abstract: The present invention relates to a method of improving the energy status of an individual by enhancing the usage of lactate. Improved lactate usage is accomplished through a composition comprising lactate precursors, adrenergic receptor agonists and insulinotropic agents.Type: ApplicationFiled: July 2, 2010Publication date: March 10, 2011Applicant: Northern Innovations and Formulations Corp.Inventors: Jason Peters, Michele Molino
-
Patent number: 7897641Abstract: A composition is disclosed which is suitable for the prevention and/or treatment of cell and tissue abnormalities of exogenous, toxic or metabolic origin and suitable for reducing the toxic effects of cyclosporin-A and other immunosuppressive agents, which may take the form of a food supplement or of an actual medicine, containing as its active ingredients in combination or separately packaged: (a) propionyl L-carnitine or one of its pharmacologically acceptable salts, and (b) an amino acid selected from the group consisting of glycine, serine, alanine and arginine, or mixtures thereof.Type: GrantFiled: February 20, 2001Date of Patent: March 1, 2011Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventor: Claudio Cavazza
-
Patent number: 7888372Abstract: The key function of TNAP in bone is degradation of PPi to remove this mineralization inhibitor and provide free phosphate for apatite deposition. PC-1 is a direct antagonist of TNAP function. ANK also antagonizes TNAP-dependent matrix calcification. Specifically, the activity of PC-1 inhibits initial MV apatite deposition, but ANK inhibits propagation of apatite outside the MVs. Furthermore, loss of function of the two distinct skeletal TNAP antagonists, PC-1 and ANK, ameliorates TNAP deficiency-associated osteomalacia in vivo. Conversely, the hyperossification associated with both PC-1 null mice and ANK-deficient (ank/ank) mice is ameliorated by deficiency of TNAP in vivo.Type: GrantFiled: April 28, 2003Date of Patent: February 15, 2011Assignees: National Institutes of Health (NIH), The Regents of the University of CaliforniaInventors: Jose Luis Millan, Robert Terkeltaub
-
Publication number: 20110034421Abstract: The present invention is directed to a third generation form of creatine, specifically a creatine hydrochloride salt, that drives significant improvements in muscle development and recovery due to its enhanced bio-availability, while causing fewer negative side effects compared to previous forms of creatine.Type: ApplicationFiled: October 21, 2010Publication date: February 10, 2011Inventors: Donald W. Miller, Jonathan L. Vennerstrom, Mark C. Faulkner
-
Publication number: 20110028553Abstract: Methods of treating at least one condition chosen from pain, inflammation, and fever in a critically ill patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen using a first dosage regimen, wherein the first dosage regimen produces a first pharmacokinetic profile in critically ill patients that is about equivalent to a second pharmacokinetic profile produced by administration of the intravenous pharmaceutical composition using a second dosage regimen of ibuprofen to non-critically ill patients, wherein the at least one condition of the critically ill patient is thereby treated.Type: ApplicationFiled: December 23, 2009Publication date: February 3, 2011Applicant: Cumberland Pharmaceuticals Inc.Inventors: Leo PAVLIV, Amy Dix Rock
-
Publication number: 20110028548Abstract: The present invention generally relates to the improvement of tissue health by increasing local blood flow. In some aspects of the invention, increased local blood flow is effected by the transdermal delivery of the nitric oxide precursor L-arginine and/or its derivatives alone, or optionally in conjunction with an adjunct such as theophylline. The transdermal delivery is effected, in certain embodiments through the means of a hostile biophysical environment, such as that created by a high ionic strength environment. Various pathological states caused by, or occurring in conjunction with, insufficient blood flow, can be treated using the systems and methods of the invention as described herein. In other embodiments, increased blood flow using the systems and methods of the invention may result in enhanced healing, for example, through greater availability of the constituents of the blood.Type: ApplicationFiled: October 8, 2010Publication date: February 3, 2011Applicant: Strategic Science & Technologies, LLCInventor: Eric Thor Fossel
-
Publication number: 20110008306Abstract: The present invention provides methods of treating creatine responsive states, such as a neurological disorder (i.e., Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis and creatine transporter defect) or a skin disorder, by administering a creatine-ligand compound, alone or in combination with an anti-inflammatory compound, to a subject.Type: ApplicationFiled: February 2, 2010Publication date: January 13, 2011Inventor: Belinda Tsao NIVAGGIOLI
-
Publication number: 20110009346Abstract: Provided are compositions comprising beta-alanylhistidine peptides and/or beta-alanines, and methods for administering these peptides and amino acids. In one aspect, the compositions and methods cause an increase in the blood plasma concentrations of beta-alanine and/or creatine.Type: ApplicationFiled: August 10, 2010Publication date: January 13, 2011Inventors: Roger Harris, Mark Dunnett
-
Patent number: 7863336Abstract: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.Type: GrantFiled: July 14, 2010Date of Patent: January 4, 2011Assignee: Neuroderm, Ltd.Inventors: Oron Yacoby-Zeevi, Mara Nemas
-
Publication number: 20100329997Abstract: The present invention relates to the use of creatine compounds such as, for example, creatine, creatine phosphate or analogs of creatine, such as creatine-pyruvate, creatine-ascorbate, cyclocreatine, 3 guanidinopropionic acid, guanidinoacetate, homocyclocreatine, guanidino benzoates as energy generating systems and antioxidants for preservation of skin against adverse aging effects and damage secondary to insults such as harmful sun radiations, stress and fatigue. The creatine compounds which can be used in the present method include (1) creatine, creatine phosphate and analogs of these compounds which can act as substrates or substrate analogs for creatine kinase; (2) molecules that mimic the biological activity of creatine (3) molecules that modulate the creatine kinase system.Type: ApplicationFiled: January 19, 2010Publication date: December 30, 2010Applicant: AVICENA GROUP, INC.Inventor: Rima KADDURAH-DAOUK
-
Publication number: 20100317737Abstract: The application of L-arginine and its derivatives to the skin causes beneficial effects of wound healing, increasing erectile function and increased growth of hair when applied in sufficient quantity to the skin. A hostile biophysical agent may be combined with the L-arginine to increase its absorption into the skin. The desired concentrations of the hostile biophysical agent is increased when concentration of L-arginine is less than 20% of the concentration of the substance applied to maximize its effect.Type: ApplicationFiled: July 9, 2010Publication date: December 16, 2010Applicant: Strategic Science & Technologies, LLCInventor: Eric T. Fossel
-
Publication number: 20100316726Abstract: The invention provides a method of treating sensitive teeth comprising attaching a sealant composition comprising a basic amino acid to a person's tooth and allowing the basic amino acid to be slowly released over time in order to reduce chrome and/or acute tooth sensitivity together with compositions and methods of use.Type: ApplicationFiled: February 6, 2009Publication date: December 16, 2010Applicant: COLGATE-PALMOLIVE COMPANYInventors: Michael Prencipe, Belle Mead Scott Robinson, Rajnish Kohli, Richard J. Sullivan
-
Publication number: 20100316712Abstract: The invention relates to the improvement in the treatment of certain neural disorders/diseases, such as Parkinson's disease and other motor disorders. The invention relates to drug compositions and dosage forms comprising said drug composition; methods of manufacturing the drug compositions and dosage forms; and methods of treatment, comprising administering the drug composition and dosage form to an individual. In certain embodiments, the drug compositions and dosage forms comprise carbidopa and levodopa in a formulation suitable for once-daily administration.Type: ApplicationFiled: December 21, 2007Publication date: December 16, 2010Applicant: Combinatorx, IncorporatedInventors: Avinash Nangia, Jules Jacob, James Yeh, Peyman Moslemy, Daya D. Verma, Dinesh K. Haswani, Ze'ev Shaked